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| INTRODUCTION
Atrophic gastritis is a loss of appropriate glands of the gastric mucosa, which are replaced by connective tissue and/or intestinal-type epithelium (intestinal metaplasia).
1 Atrophic gastritis, which is usually caused by Helicobacter (H.) pylori or may have an autoimmune origin, pre-disposes to gastric cancer and impairs gastric physiology leading to hypo-or achlorhydria, iron and vitamin B 12 malabsorption. 2 It is well known that the intestinal-type gastric adenocarcinoma develops in a stepwise manner with a sequence of events that evolves from atrophic gastritis and intestinal metaplasia to dysplasia and carcinoma.
International guidelines recommend endoscopic follow-up and gastric biopsies for subjects with atrophic gastritis, even after H. pylori eradication, to early detect gastric cancer and reduce mortality. 2, 3 However, identifying subjects with an underlying atrophic gastritis is still an issue. Gastroscopy and histology are the reference standard, but the use of endoscopy as a screening test is costly, uncomfortable and does not have good patient's compliance. 2 International guidelines and a recent global consensus report have agreed that serological tests may be very useful to identify individuals with atrophic gastritis. [2] [3] [4] A non-invasive tool able to easily identify individuals with atrophic gastritis, or those who are very likely to carry such precancerous lesion, is essential for improving the early diagnosis of gastric cancer. Such test would be ideal for screening subgroups of subjects, such as those with a positive family history, or populations at high risk of gastric cancer, to identify those patients which must undergo endoscopy. In addition, an accurate non-invasive test would be very helpful to improve our knowledge on the epidemiology of atrophic gastritis in the general population.
Over the last decade, the combination of serological assays including pepsinogen, gastrin-17 (G-17) and anti-H. pylori antibodies (panel test) has been proposed as a non-invasive test for the diagnosis of atrophic gastritis. [2] [3] [4] The rationale of this test is based on the fact that pepsinogen-I (PG-I) is secreted only by oxintic glands of the corpus mucosa, while pepsinogen II (PG-II) is also produced in the gastric antrum and duodenum, and that gastrin-17 is only secreted by the G cells of the antral mucosa. Serum PG-I levels and/or the PG-I/PG-II ratio seem to be lower in patients with corpus atrophic gastritis, whereas a low G-17 serum level, in combination with positive anti-H. pylori antibodies (HpAb), would indicate the presence of antrum atrophic gastritis. 5 Thus the combination of the results of HpAb, PG-I or PGI/PGII ratio, and G-17 tests would allow us to detect the presence and site of atrophic gastritis. 5 However, although the panel test is commercially available and used in many countries worldwide, in particular in Europe, the diagnostic reliability of this test remains uncertain. Clarifying the diagnostic performance of this test is essential for its use in individuals and in the general population for gastric cancer screening and epidemiological studies on the prevalence and incidence of atrophic gastritis.
The aim of this study was to carry out a systematic review and meta-analysis to determine the diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-H. pylori antibodies serum assays for the diagnosis of atrophic gastritis in adults. The primary outcome was to assess the diagnostic performance for the diagnosis of atrophic gastritis regardless of the location. The secondary outcome was to determine the accuracy in detecting the site of atrophic gastritis.
| METHODS
We performed a systematic review and a meta-analysis following the recommendations of the Cochrane Collaboration's Diagnostic
Test Accuracy Group. 6 2.1 | Search strategy and study selection
We searched MEDLINE via PubMed, Ovid Embase, the Cochrane Library and Scopus databases up to 31st December 2016. The electronic search of literature was performed using the following keywords: "pepsinogens," "pepsinogen I," "pepsinogen II," "gastrin," "panel test" or "gastropanel," and "atrophic gastritis," "gastric atrophy," "intestinal metaplasia," "gastric precancerous condition" or "gastric precancerous lesion." The search strategies are reported in Appendix S1. Two authors (RMZ and LHE) did the initial selection on the basis of titles and abstracts. Subsequently, they independently performed a detailed full text assessment of potentially relevant studies, with any disagreement resolved through discussion or arbitration by a third reviewer (FB).
For the inclusion in the review, we selected studies if they met the following pre-specified criteria: diagnostic studies evaluating the accuracy of the combination of pepsinogen, gastrin-17 and anti-H.
pylori antibodies serological assays for the diagnosis of atrophic gastritis in adults using the histological diagnosis of atrophic gastritis according to the updated Sydney System as reference standard. 1 We excluded studies that did not meet the inclusion criteria or whether essential information was missing and could not be obtained by the authors.
| Data extraction and quality assessment
Two authors (RMZ and SR) extracted independently relevant data on the publication, study methods and results using a standardised data extraction form. We constructed 2 9 2 tables that contained the number of cases found to be true positives (subjects with positive used for defining the target condition. When multiple articles for a single study were found, the latest publication was considered and supplemented, if necessary, with data from the previous publications.
Two authors (RMZ and SR) independently assessed the methodological quality of the included studies using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool (Appendix S2). 8 We evaluated, in particular, the presence of potential bias in patient selection, blinding to the histological diagnosis, description of the reference standard and inclusion of all patients in the analysis. Any disagreements were resolved through discussion and, if necessary, arbitration by a third reviewer (FB).
| Statistical analysis
Using 2 9 2 tables, we calculated sensitivity and specificity with 95% confidence intervals (95% CI) for each study, and created coupled forest plots for showing each set of data. We calculated summary estimates of sensitivity and specificity, positive and negative likelihood ratio using a random effect bivariate model and we fit a summary hierarchical receiving operating characteristic (HSROC) curve. 9, 10 We used summary estimates of sensitivity and specificity to estimate the summary negative and positive predictive values based on the median prevalence (pre-test probability) of atrophic gastritis across the studies, which was calculated from the median prevalence of the included studies.
We explored heterogeneity between studies through visual examination of the forest plot and HSROC curve. 6 We planned to explore the following sources of heterogeneity adding them as covariates, if appropriate, to a bivariate regression model: index test, target condition, setting, study design, country, use of PPIs, type of publication and methodological quality. We performed sub-group analyses for any covariates that showed a statistically significant association with the summary estimates. We performed separate meta-analyses to assess the performance of the panel test for the diagnosis of the site of atrophic gastritis:
antrum-limited atrophic gastritis, corpus-limited atrophic gastritis, and both antrum and corpus atrophic gastritis. We used Cook's distance to check for particular influential studies and produced a scatter plot of the standardised level 2 residuals to check for outliers. 11 We did not investigate publication bias as standard funnel plot and tests for publication bias are not recommended in meta-analysis of diagnostic test accuracy studies. 6 All analyses were performed with STATA version 14 (StataCorp, College Station, TX, USA).
| RESULTS
The electronic search identified 3924 records after duplicates were removed, of which 38 full text articles were assessed for eligibility. 5, 7, One additional full text article identified from the reference list of the manufacturer's website of GastroPanel (Biohit Plc)
was also assessed for eligibility. 48 Of the 39 articles, 15 met the criteria for the inclusion in the review. 7, 12, 15, [18] [19] [20] 23, 26, 30, 33, 35, 38, 42, 47, 48 In addition, a total of five abstracts that met inclusion criteria were identified from the conferences proceedings. [49] [50] [51] [52] [53] Finally, a total of 20 studies consisting of 15 papers and five abstracts were included in the meta-analysis. Figure 1 shows the flow chart of references through the selection process and the reasons for study exclusion.
| Study characteristics
The 20 included studies involved a total of 4241 participants, with 1143 having the target condition. The mean age of participants ranged from 39 23 to 65 years 15 and the proportion of men from 20% 52 to 58.6%. 30 The mean prevalence of atrophic gastritis in the included studies ranged from 8.1% 38 Eleven studies used as target condition atrophic gastritis regardless of the grade of severity (from mild to severe atrophy), 18, 20, 23, 33, 38, 42, [47] [48] [49] [50] 52 seven studies used moderate-severe atrophic gastritis 7, 12, 19, 26, 30, 35, 51 and two studies reported the results for both target conditions separately.
15,53
Regarding the index test, 14 studies measured the fasting serum level (basal) of G-17 (G-17b), 19, 20, 23, 26, 30, 33, 35, 38, 42, 47, [50] [51] [52] [53] while six studies measured the serum level of stimulated G-17 (G17s) taking a blood sample after a protein reach drink. 7, 12, 15, 18, 48, 49 Thirteen studies used PGI 7, 12, 15, [18] [19] [20] 33, 35, 42, [48] [49] [50] 53 while seven studies used both PGI and PGI/PGII ratio. Table S1 and Table S2 show the results of the assessment of methodological quality of the included studies. All studies, but one, 33 were at "high risk" or "unclear risk" in one or more domains concerning bias or applicability to the review question (Table S2 ). Most studies were at high risk of bias in the selection of participants, mainly because they did not enrol a consecutive or random sample of subjects. In addition, about half of studies did not include all participants in the final analysis or did not report the time interval between gastroscopy and blood sampling, and 89% (95%CI 78% to 99%) with the use of PPIs. The use of PGI/ PGII ratio (P = .12), moderate-severe atrophic gastritis as target condition (P = .22), setting (P = .80), study design (P = .09), country (P = .29) and the type of publication (P = .36), on the other hand, had not effect on the summary estimates.
After calculation of summary estimates we produced Cook's distance to identify influential studies. Cook's distance showed that the study by Peitz 35 was particularly influential, followed by the study by Pasechnikov 18 and the study by Goni 53 ( Figure 4) . All the three studies were identified as outliers having the largest standardised residuals for sensitivity, with the study by Peitz being an outlier also for specificity ( Figure S1 ). However, after exclusion of the study by Figure S4 ), respectively.
| DISCUSSION
This meta-analysis included 20 studies assessing the accuracy of the combination of pepsinogens, gastrin-17 and anti-H. pylori antibodies serum assays for the diagnosis of atrophic gastritis, compared to histology; pooling data from these studies yielded a summary sensitivity of 74.7% (62.0% to 84.3%) and a summary specificity of 95.6%
(92.6% to 97.4%). Based on the median prevalence of atrophic gastritis across the studies of 27%, which is very close to that estimated worldwide in the general population (around 30%), 54 the negative predictive value of the panel test was 91% and the positive predictive value was 86%; this implies that 91 of 100 subjects with a negative test will be true negative for the presence of atrophic gastritis, while 86 of 100 subjects with a positive test will be true positive.
Using the pooled likelihood ratios, with a median pre-test probability of atrophic gastritis of 27%, the post-test probability was 9% for subjects with a negative test and 86% for subjects with a positive test result.
Pooling data from seven studies produced a summary sensitivity of the panel test of 65.4% for the diagnosis of antrum atrophic gastritis, 70.4% for the diagnosis of corpus atrophic gastritis and 42.6%
for both antrum and corpus atrophic gastritis; the summary specificity was higher than 95% for any site of atrophic gastritis.
| Strengths and weaknesses of the study
A strength of this review is the comprehensive search of literature without restrictions on the language of publications; we also identified and included unpublished studies, which were reported as abstracts in international conferences proceedings, minimising the risk of missing relevant studies. As there is not a powerful method of testing for publication bias in a meta-analysis of diagnostic accuracy studies, 6 we are not able to assess the likely impact of unpublished studies on our results. However, the studies included in this systematic review are likely to be the majority on this topic and, in that is recommended for meta-analysis of diagnostic accuracy studies. 6, 9 A weakness of our findings was the substantial heterogeneity between the results of the studies, in particular for sensitivity. However, a substantial between-study heterogeneity is a commonplace in meta-analysis of diagnostic test accuracy studies. The metaregression analysis showed that the measurement of serum G-17 and the use of PPIs were significant sources of heterogeneity. A relevant finding of our meta-analysis was that the measurement of stimulated gastrin-17 with a protein rich drink increased the sensitivity of the test; the summary sensitivity of the panel test increased to 91% with G-17s. Our finding is in line with previous reports that showed that the use of a protein rich meal before the blood sampling improved the performance of G-17 as a biomarker of antrum atrophic gastritis. 13, 14, 16 It is well known that several factors, such as a physiologic high acid secretion, are involved in the output of G-17 from the antral G cells. 5 The protein stimulus, which usually increases the secretion of G-17, may help distinguishing if a low G-17 serum level is really due to the antrum atrophic gastritis with consequent loss of G cell (G-17 is still low after protein stimulus) or instead it is due to other factors, such as a high acid secretion (G-17 is higher after protein stimulus). 5, 55 Our finding suggests that the measurement of serum level of stimulated G-17 could improve the diagnostic performance of the panel test, likely improving its sensitivity in the diagnosis of antrum atrophic gastritis.
We also found that the use of PPIs markedly reduced the sensitivity of the panel test. It is well known that PPIs increase serum levels of G-17 through the reduction in hydrochloric acid; in addition, the trophic effect of the gastrin on parietal cells increases serum levels of pepsinogens 5, 29 ; these are the likely reasons that could explain the increased probability of false negative results due to the use of PPIs.
Unfortunately, only few studies with a small sample size assessed the reliability of the test for the diagnosis of the location of atrophic gastritis; with this limitation, we found a slightly lower sensitivity of the panel test in detecting the site of atrophic gastritis, except for cases with both antrum and corpus atrophic gastritis where the sensitivity of the test was very low (42.6%). Moreover, the sensitivity of the test in diagnosing antrum-limited atrophic gastritis was just slightly lower than corpus-limited atrophic gastritis (65.4% vs 70.4%).
Another weakness of our meta-analysis is that our findings are based on studies with low methodological quality. Most studies did not enrol a consecutive o random sample of subjects; thus, the pres- F I G U R E 3 Summary receiver operating characteristics plot of sensitivity and specificity for atrophic gastritis regardless of the site. Each circle indicates an individual study and it is sized according to the total number of subjects; solid spot in middle is summary sensitivity and specificity; inner and outer ellipses indicate 95% confidence region and prediction regions, respectively Including only studies that used the Updated Sydney system, we have, most likely, reduced the heterogeneity between studies and minimised the introduction of bias related to the reference standard. 8 In the previous meta-analysis, another limitation was the lack of assessment of the methodological quality of the included studies, which is essential for assessing the strength of the results. In contrast, we carried out an appropriate assessment of the quality of studies using the recommended QUADAS-2 tool. 6, 8 Finally, Syrjanen used traditional meta-analysis applications which essentially consist in pooling weighted averages of sensitivities and specificities across all studies. As well known, meta-analyses of data from diagnostic accuracy studies require more complex and rigorous statistical methods that account for the correlation between sensitivity and specificity, that is, multilevel statistical approaches. 6,9,10 To achieve meaningful summary estimates of sensitivity and specificity, we have indeed used such multilevel statistical methods.
The meta-analysis by Syrianen reported a low sensitivity (51.6%) for the diagnosis of antrum atrophic gastritis with a better sensitivity (70.2%) for corpus atrophic gastritis. We found a similar sensitivity for corpus atrophic gastritis (70.4%), but a higher sensitivity for the diagnosis of antrum atrophic gastritis (65.4%).
Two different meta-analyses assessed the diagnostic performance of pepsinogens 57 and gastrin-17 serum assays separately. 55 The pooled sensitivity and specificity were, respectively, 69% and 88% for pepsinogens and 48% and 79% for gastrin-17 tests. The panel test seems to have a higher sensitivity (74.7%) and specificity (95.6%) than serum pepsinogens and gastrin-17 tests alone, and this is likely due to the use of both biomarkers of atrophic gastritis.
| Conclusions and implications
The results of this meta-analysis suggest that the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays is a reliable tool for the diagnosis of atrophic gastritis.
Given a prevalence (pre-test probability) of atrophic gastritis of 27%, the panel test would miss only nine subjects for every 100 with atrophic gastritis (negative predictive value = 91%). We also However, well-designed high quality studies with a large sample size are needed to confirm the performance of the panel test in the diagnosis of atrophic gastritis, especially in Asia and America.
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